NAD+ downregulation claims: what the science actually says

What's this video probably claiming?

Based on the caption and hashtag cluster, this creator is almost certainly pushing a cycling protocol for NAD+ supplementation, specifically the idea that continuous use will cause your body to downregulate its own NAD biosynthesis pathways. The framing is classic biohacking rhetoric: use the compound, then back off to "protect" your natural production. The hashtags include mots-c and peptide therapy references, which suggests the video likely recommends pairing NAD+ with MOTS-c, a mitochondrial-derived peptide, as an alternative or complement during off-cycles. The creator describes NAD+ as a peptide, which is technically incorrect from the start. NAD+ is a coenzyme, not a peptide. That's not a minor slip. It tells you something about the precision of everything else being claimed here.

What does the science actually show?

NAD+ levels do decline with age. That part is real. Yoshino et al. (2018, Cell Metabolism) confirmed age-associated NAD decline in humans and showed that NMN supplementation raised NAD+ levels in skeletal muscle in a small 10-week RCT. Separately, Martens et al. (2023, Nature Aging) found that 300mg daily NMN for 10 weeks was safe and raised blood NAD+ levels in middle-aged adults, though functional performance gains were modest. What the research does not support is the specific claim that exogenous NAD+ supplementation downregulates endogenous biosynthesis over time. That feedback loop hypothesis is borrowed loosely from endocrine pharmacology, like how exogenous testosterone suppresses the HPG axis. NAD+ metabolism does not operate through the same receptor-mediated negative feedback mechanisms. There is currently no peer-reviewed human evidence that NAD+ precursor supplementation suppresses NAMPT activity or the salvage pathway in a clinically meaningful way.

Where does the social media noise diverge from clinical reality?

The downregulation narrative is almost entirely theoretical extrapolation dressed up as established fact. Biohacking communities have borrowed the concept of "receptor downregulation" and applied it broadly to supplements without evidence that the underlying mechanism exists for NAD+ pathways. MOTS-c, the peptide hinted at in the hashtags, is genuinely interesting research-wise. Lee et al. (2015, Cell Metabolism) identified MOTS-c as a mitochondrial peptide that regulates metabolic homeostasis in mice, and animal data suggests roles in insulin sensitivity and exercise capacity. But human clinical trials are essentially nonexistent at this point. Recommending MOTS-c as a cycling strategy alongside NAD+ is extrapolating from mouse studies to human protocols, which is a significant leap. The energy, recovery, and mental clarity claims are also entirely anecdotal here. No RCT has demonstrated those three outcomes together from IV or oral NAD+ supplementation in otherwise healthy adults.

What should you actually know?

NAD+ precursor supplements like NMN and NR have a legitimate and growing evidence base for raising circulating NAD+ levels. The clinical question is whether raising those levels actually translates to meaningful health outcomes in non-deficient adults, and that evidence is still thin. Supplementing with NAD+ or its precursors appears to be reasonably safe at studied doses, based on current data. The cycling concept being promoted here lacks any mechanistic evidence in humans. If you are considering NAD+ therapy, the conversation belongs with a licensed clinician who can assess your baseline, not a TikTok creator stacking unproven peptides. MOTS-c specifically remains an investigational compound with no approved clinical use. Framing it as a complement to NAD+ cycling is promotional, not evidence-based. The regulatory status of compounded peptides varies significantly, and that context is absent from this video entirely.